Uso de analgesia transdérmica en pacientes con necesidades paliativas
DOI:
https://doi.org/10.26423/rcpi.v7i2.289Keywords:
Dolor, analgesia, parches transdérmicos, cuidado paliativoAbstract
Comprehensive treatment of pain is multimodal, and the pharmacotherapy plays a key role. An effective therapy for the pain depends on the intensity and kind of pain, comorbidities and the appropriate choice of the analgesic, its dosage and the route of administration. It has been observed through the studies analyzed in different articles the importance of the use of transdermal analgesia in patients with palliative needs, this review aims to present the identification of the benefits or advantages of the use of analgesia in patients with palliative needs, to determine the disadvantages of the use of transdermal analgesia and describe the main factors that intervene in the non-adherence of the transdermal analgesia treatment. Analgesics that were administered Transdermally or topically act through different mechanisms. Opioids that administered transdermally are absorbed in the vessels located in the subcutaneous tissue and, subsequently, they are transport in the blood to the opioid receptors, located in the central and peripheral nervous system, which shows us a better adherence in the treatment of the patient, allowing us to evaluate the benefits of the use of buprenorphine and fentanyl patches, showing as a result the adequate control of pain and thus providing a better quality of life. On the other hand, analgesics administered topically have a much better profile for the adverse effects because they relate to minimal systemic effects.
Downloads
References
Institut Catala d Oncologia (2011,septiembre) Principios de la atención paliativa; Pág 6-8, Disponible en http://ico.gencat.cat/web/.content /minisite/ico/professionals/documents/qualy/arxius/doc_principios_basicos_de_la_atencion_paliativa_vf.pdf
Ramírez C. Neuroticismo, afrontamiento y dolor crónico. Anales de Psicología 2001; 17(1): 129-137. Disponible en http://www.redalyc.org/pdf/167/ 16717110.pdf
Rondero A. What do you know about… transdermal drug delivery? Revista mexicana de ciencias farmacéuticas. 2011; 42 (1): 65-68. Disponible en http://www.scielo.org.mx/pdf/rmcf/v42n1/v42n1a8.pdf
Lampert A, Kessler J, Washington P, Bardenheuer H, Bocek E, Krisam J, et al. Patient Experiences With Handling of Analgesic Transdermal Patches and Challenges in Correct Drug Administration: A Pilot Study on Patient Education. J Patient Saf. 2018; 14 (4): 97-101. Disponible en https://www. ncbi.nlm.nih.gov/pubmed/30451718 DOI: https://doi.org/10.1097/PTS.0000000000000538
Traveset. CedimCat. 2016. Disponible en https://es.scribd.com/document/127280633/ADMINISTRACION-DE-MEDICAMENTOS-FRAC CIONADOS-pdf
Alaba J, Arriola E. Guía farmacoterapéutica para pacientes geriátricos. 2012; 209 p. Disponible en https://www.osakidetza.euskadi.eus/contenidos/ informacion/publicaciones_informes_estudio/es_pub/adjuntos/guia_pacientes_geriatricos.pdf
Noreña A, Alcaraz N, Rojas J. Aplicabilidad de los criterios de rigor y éticos en la investigación. Aquichan. 2012; 12 (3): 263-274. Disponible en https://www.redalyc.org/articulo.oa?idp=1&id=74124948006&cid=38214 DOI: https://doi.org/10.5294/aqui.2012.12.3.5
Singh J. Critical appraisal skills programme. J Pharmacol Pharmacother 2013;4:76-7 Disponible en: https://www.researchgate.net/publication/274546524_Critical_Appraisal_Skills_Programme_CASP_Appraisal_Tools DOI: https://doi.org/10.4103/0976-500X.107697
Samala R, Bloise R, Davis M, et al. Efficacy and safety of a six-hour continuous overlap method for converting intravenous to transdermal fentanyl in cancer pain. J Pain Symptom Manage. 2014; 48(1): 132-6. https://doi.org/10.1016/j.jpainsymman.2013. 09.001 DOI: https://doi.org/10.1016/j.jpainsymman.2013.09.001
Schmidt M, Taubert M, Bromham N, Hilgart J, Arnold S, et al. The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review. BMJ Supportive & Palliative Care. 2016; 6 (3): 292-306. Disponible en http://dx.doi.org/10.1136/bmjspcare-2015-000939 DOI: https://doi.org/10.1136/bmjspcare-2015-000939
Kakali C, Partha D, Nishana P, Krishnangshu B, Shampa M. A comparative study of transdermal buprenorphine and oral morphine in the treatment of chronic pain of malignant origin. Indian Journal Of Palliative care. 2018; 24 (4): 500-504. Disponible en http://www.jpalliativecare.com/searchresult.asp?search=&author=kakali&journal=X&but_search=Search&entries=10&pg=1&s=0 DOI: https://doi.org/10.4103/IJPC.IJPC_83_18
Kuip E, Oldenmenger W, Visser-Thijs M, de Bruijn P, Oomen-de Hoop E, Mathijssen R, Van der Rijt C, Koolen S. Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl. Oncotarget. 2018; 9 (26): 18269-18276. https://doi.org/10.18632/oncotarget.24812 DOI: https://doi.org/10.18632/oncotarget.24812
Tornero C, Herrera J, Molà O, Galván J. Buprenorfina transdérmica (Feliben®): Nueva opción terapéutica para pacientes con dolor moderado y severo. Rev. Soc. Esp. Dolor. 2012; 19 (6): 301-309. Disponible en: http://scielo.isciii.es/pdf/dolor/v19n6/original3.pdf
Cadena M. Utilidad de la Buprenorfina transdérmica en el manejo del dolor oncológico. ION SOLCA Dr. Juan Tanca Marengo. 2010-2012. Disponible en: http://repositorio.ug.edu.ec/ handle/redug/37025
Ahn J, Lin J, Ogawa S, Yuan C, O'Brien T, Le BH, et al. Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. J Pain Res. 2017; 2017(10): 1963-1972. Disponible en: https://doi.org/10.2147/JPR.S140320 DOI: https://doi.org/10.2147/JPR.S140320
Leppert W, Malec–Milewska M, Zajaczkowska R, Wordliczek J. Transdermal and Topical Drug Administration in the Treatment of Pain. Molecules. 2018; 23(3): 681. https://doi.org/10.3390/ molecules23030681
Golčić M, Dobrila-Dintinjan R, Golčić G, Gović-Golčić L, et al. Differences between Transdermal Fentanyl and Buprenorphine in the Elderly Hospice Patient. 2018; 2018(1):1-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205095 DOI: https://doi.org/10.1155/2018/8610538
Kestenbaum M, Vilches A, Messersmith S, Connor S, Fine P, Murphy B, et al. Alternative Routes to Oral Opioid Administration in Palliative Care: A Review and Clinical Summary. Pain Medicine. 2014; 15(7): 1129–1153. https://doi.org/10.1111/pme.12464. DOI: https://doi.org/10.1111/pme.12464
Roberto A, Greco M, Legramandi L, Galli F, Galli M, Corli O. A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis. J Pain Res. 2017; 10: 2123–2133. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590764/ DOI: https://doi.org/10.2147/JPR.S141928
Arnet I, Schacher S, Balmer E, Koeberle D, Hersberger K. Poor adhesion of fentanyl transdermal patches may mimic end-of-dosage failure after 48 hours and prompt early patch replacement in hospitalized cancer pain patients. J Pain Res. 2016; 9: 993-999. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108613/ DOI: https://doi.org/10.2147/JPR.S116091
Reddy A, Yennurajalingam S, Reddy S, Wu J, Liu D, Dev R, et al. The Opioid Rotation Ratio From Transdermal Fentanyl to "Strong" Opioids in Patients With Cancer Pain. J Pain Symptom Manage. 2016 Jun; 51(6):1040-5. Disponible en https://www.ncbi.nlm.nih.gov/pubmed/26826675 DOI: https://doi.org/10.1016/j.jpainsymman.2015.12.312
Husic S, Imamovic S, Matic S, Sukalo A. Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care. Med Arch. 2017; 71(4): 246-250. https://www.ncbi.nlm.nih.gov/pub med/28974843 DOI: https://doi.org/10.5455/medarh.2017.71.246-250
Leppert W, Malec M, Zajaczkowska R, Wordliczek J, et al. Transdermal and Topical Drug Administration in the Treatment of Pain. Molecules. 2018; 23(3): 681. https://doi.org/10.3390/molecules/23030681 DOI: https://doi.org/10.3390/molecules23030681
Leppert W. A successful switch from transdermal fentanyl to transdermal buprenorphine in a patient with neuropathic pain: a case report. Am J Hosp Palliat Care. 2014; 31(1): 101-4. https://doi.org/10.1177/1049909112472722 DOI: https://doi.org/10.1177/1049909112472722
Mercadante S, Porzio G, Ferrera P, Aielli F, Adile C, Ficorella C, et al. Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin. 2010; 26(12): 2765-8. https://doi.org/10.1185/03007995.2010.532545 DOI: https://doi.org/10.1185/03007995.2010.532545
Pergolizzi J, Scholten W, Smith J, Leighton-Scott J, Willis J, Henningfield J. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiologica Taiwanica. 2015; 53(2): 71-76. https://doi.org/10.1016/j.aat.2015.06.001 DOI: https://doi.org/10.1016/j.aat.2015.06.001
Rodríguez R, Daza P, Rodríguez M. Uso de buprenorfina transdérmica en el alivio del dolor por cáncer. Rev. Colomb. Anestesiol. 2006; 34 (4); 253-257. http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-33472006000400005& lng=en.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 MAGAZINE SCIENCE AND INNOVATION TEACHING
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
El titular de los derechos de autor de la obra, otorga derechos de uso a los lectores mediante la licencia Creative Commons Atribución-NoComercial-CompartirIgual 4.0 Internacional. Esto permite el acceso gratuito inmediato a la obra y permite a cualquier usuario leer, descargar, copiar, distribuir, imprimir, buscar o vincular a los textos completos de los artículos, rastrearlos para su indexación, pasarlos como datos al software o usarlos para cualquier otro propósito legal.
Cuando la obra es aprobada y aceptada para su publicación, los autores conservan los derechos de autor sin restricciones, cediendo únicamente los derechos de reproducción, distribución para su explotación en formato de papel, así como en cualquier otro soporte magnético, óptico y digital.
